Addex Therapeutics Ltd. (ADXN) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$3.37

From 52W high−68.95%

Volume2112.00

Market cap$5.96M

P/E (TTM)—

P/S (TTM)66.4x

Div yield—

Key dataSep 18, 2026

Open

$3.37

From 52W high

−68.95%

Volume

2112.00

Market cap

$5.96M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

32.4

MomentumView details →

1D Return

+1.19%

YTD Return

−56.22%

SummaryUpdated Mar 1, 2026

Addex Therapeutics Ltd (NASDAQ:ADXN) is a Swiss development-stage biopharmaceutical company founded in 2002 and headquartered in Geneva. The company specializes in discovering and developing small-molecule pharmaceutical products targeting central nervous system disorders through its proprietary allosteric modulation technology platform. After going public in February 2020, Addex has evolved from a traditional biotech focused on advancing its own pipeline to a more asset-light model, having spun out its preclinical programs into Neurosterix in 2024 while retaining key partnerships and a focused development strategy.

Ask drillr about Addex Therapeutics Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

55.1x

P/S (TTM)

66.4x

P/B (TTM)

1.5x

ProfitabilityView details →

Gross Margin

−265.47%

Net Margin

−9410.20%

EBITDA Margin

−9538.96%

ROE (TTM)

−211.98%

ROA (TTM)

−146.39%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

−56.61%

EPS YoY

—

FCF YoY

+38.42%

Revenue CAGR 3Y

−72.38%

EPS CAGR 3Y

—

EBITDA YoY

−29.55%

MomentumView details →

1D Return

+1.19%

YTD Return

−56.22%

1Y Return

−62.40%

RSI (14)

32.4

vs 50D SMA

−31.64%

vs 200D SMA

−48.33%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

0.97x

Quick Ratio

0.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.53

EPS Surprise

—

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

−4459.84%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

74038.00

Net Income (TTM)

−6.97M

Op. CF (TTM)

−2.33M

Next earningsNov 9, 2026 →

Latest newsMore news →

Addex Therapeutics raised USD 2.8 million in gross proceeds through the sale of 437,869 ADSs under its At the Market offering agreement.25d ago

Similar companies

Creative Medical Technology Holdings, Inc.CELZ Cardio Diagnostics Holdings, Inc.CDIO XTL Biopharmaceuticals Ltd.XTLB Medicus Pharma Ltd.MDCXW Reviva Pharmaceuticals Holdings, Inc.RVPH Dermata Therapeutics, Inc.DRMA Find similar companies →

Latest newsMore news →

Addex Therapeutics raised USD 2.8 million in gross proceeds through the sale of 437,869 ADSs under its At the Market offering agreement.25d ago